Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over millennia of usage. “The safety profile is amazing and that’s the bit that everyone has forgotten,” Dr Hopkins says. Stockhead – Dr Boreham’s Crucible: Zelira’s…
CFN Media Interviews Zelda Therapeutics at New West Summit
Zelda Therapeutics Broker/ Shareholders’ Brefing Lunch – Perth Shareholder Briefing Invitation: 4 July, Perth
Forbes Article – Mara Gordon: Aunt Zelda’s, For Every Household
A Green Fund exclusive interview with Dr. Richard Hopkins, Managing Director of Zelda Therapeutics. Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company that aims to treat important diseases and disorders using cannabinoid-based medicines. Zelda Therapeutics – Pioneering Australian Medicinal Cannabis Research
Zelda Therapeutics Ltd (ASX:ZLD) is developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions, with a focus on cancer therapies. Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions
The Board of Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) is pleased toprovide this operational update with its Appendix 4C for the three-months to31 March 2019. March 2019 Quarterly Report
More people in Australia die from accidental drug overdoses than in road accidents. More alarmingis that prescription painkillers cause two and a half times more deaths than illicit drugs. This is amajor concern considering one in five Australians live with chronic pain. Prescription Opioid Crisis
Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF, Zelda): has expanded its human clinical trial program in a clinical trial partnership with the prestigious St Vincent’s Hospital in Melbourne to examine the potential to use certain cannabinoid medications in patients on chronic, high dose opioid pain management therapy. ASX Announcement: Zelda Partners St Vincent’s Hospital on Opioid Reduction Study
Zelda Therapeutics is developing and hopes to soon license medicinal cannabis formulations that treat common medical disorders. The Company has clinical trials underway in autism and insomnia and pre-clinical research rograms progressing in cancers of the breast, pancreas and brain and in diabetes-related cognitive decline. View full report